Research brief
Jazz Pharmaceuticals closed at $224.7 for the week ended 19 June, down 2.6% on the week and 6.3% over four weeks. The stock remains up 23.0% over 12 weeks and 109.0% over 52 weeks, but participation has faded to 0.9x average volume and Relative Strength has cooled sharply from its recent level.
- JAZZ remains in an active Trend Signal with a 39-week streak and trades 17.9% above its $190.5 weekly Trend Line.
- The close sits at 86.5% of the 52-week range, 7.7% below the $243.3 high and 67.3% above Sharemaestro Fair Value of $134.3.
- Short-term momentum has turned negative, with a 2.6% weekly decline and a 6.3% four-week loss, despite a still-positive 23.0% 12-week return.
- Volume was 4.0M shares, below both the 13-week and 52-week averages of 4.5M, leaving the latest move without strong participation confirmation.
- US Biotechnology gained 3.3% on the week and 4.5% over four weeks, making JAZZ’s short-term underperformance clear even though its 12-week return remains ahead of the industry average.
Trend remains constructive, but the near-term message has changed
Jazz Pharmaceuticals’ weekly structure is still positive, but the latest tape is no longer one-way. The NASDAQ-listed biotechnology stock closed at $224.7, leaving it 17.9% above its $190.5 Trend Line and still high in its annual range at 86.5%. That supports the broader trend case, with the Trend Signal active for 39 weeks, or 75.0% of the past year.
The issue is follow-through. JAZZ has now slipped 2.6% in the latest week and 6.3% over four weeks, pulling back from a 52-week high of $243.3. The 12-week return remains strong at 23.0%, but the short-term rank has deteriorated, with the stock sitting near the lower end of both Healthcare and Biotechnology weekly peer tables.
Biotech context makes the pullback stand out
The sector backdrop is mixed. US Healthcare fell 1.4% on the week and shows limited breadth, with only 31.0% of constituents in active weekly trends, 41.0% showing positive Market Dynamics and 25.0% showing positive Relative Strength. Against that weaker sector tape, JAZZ still holds an active trend and positive activity and RS readings.
The industry comparison is less forgiving. US Biotechnology rose 3.3% on the week, 4.5% over four weeks and 16.8% over 12 weeks, while JAZZ lost ground in the shorter windows. Its 23.0% 12-week advance remains ahead of the industry average, but the latest weekly and four-week ranks, 91st and 84th out of 100, show money rotating elsewhere in the group.
Market Dynamics and Relative Strength have cooled
Sharemaestro’s Market Dynamics read remains positive at 1.14, and the Expectancy Model is positive at 56.86%, but the rate of improvement has faded. Activity pressure is down 24.7% over four weeks, while Relative Strength, still positive at 14.98, is down 51.7% over the same period. That combination points to a constructive but less urgent setup.
The signal state is therefore balanced rather than outright strong. The trend backdrop is active, price is comfortably above trend, and activity pressure is still positive, but there is no fresh buy signal in the latest read. The stock also carries a 67.3% premium to Sharemaestro Fair Value, which can be supported during strong momentum phases but becomes a more visible risk when confirmation cools.
Volume and risk profile argue for patience in the next read
Participation did not validate the latest move. Volume was 4.0M shares, equal to 0.9x the 13-week average and 0.9x the 52-week average, versus 4.5M for both baselines. Earlier upside weeks saw stronger prints, including 10.5M shares on the 10.4% week in late February and 6.2M shares on the 11.4% advance in early May. The latest pullback, by contrast, came on normal-to-light volume rather than a heavy distribution print.
Risk is moderate but no longer passive. Recent weekly volatility is 3.9%, below the 52-week base of 5.1%, and the annual up/down split remains favourable at 31 positive weeks versus 21 negative weeks. Average positive weeks of 4.2% exceed average negative weeks of 2.4%. Still, nine recent reversal markers in the smart-money tape and the pullback from near the high make the next watch points clear: whether the Trend Line remains distant support, whether activity pressure stabilises, and whether any renewed move arrives on more than 1.5x volume.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/jazz-pharmaceuticals-39-week-trend-signal-short-term-rank/.
Media and research systems can follow the RSS feed or JSON feed.